6 Di­men­sions backs Lyv­gen's $30M B round; No­var­tis hands off glob­al rights to IL-2 drug

→ Shang­hai’s im­muno-on­col­o­gy drug­mak­er Lyv­gen Bio­phar­ma has scored a $30 mil­lion B round led by one of Chi­na’s most ac­tive biotech VCs — 6 Di­men­sions Cap­i­tal. Join­ing the round are new in­vestors Win­fair Glob­al and Run­ling Cap­i­tal, along with ex­ist­ing back­ers from the A round Morn­ing­side Ven­tures. Lyv­gen has an an­ti­body plat­form and an ear­ly pipeline, in­clud­ing a PD-1 an­ti­body and a set of pro­pri­etary ag­o­nist an­ti­bod­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER